Alpha Cognition Inc.
Business
Alpha Cognition Inc. is a biopharmaceutical company developing treatments for neurodegenerative diseases, primarily Alzheimer's disease. The company's lead product, ZUNVEYL (benzgalantamine), is an FDA-approved oral acetylcholinesterase inhibitor launched in March 2025, targeting long-term care facilities. Additional pipeline candidates include ZUNVEYL in combination with memantine for moderate-to-severe Alzheimer's disease, sublingual formulations, and ALPHA-1062 for mild traumatic brain injury, with development contingent on available capital.
Summary from 10-K filed 2026-03-31
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Total revenue | 10 | — | — | |
| Cost of product sales, excluding amortization of intangible asset | 474,006 | — | — | |
| Cost of licensing revenue | 1 | — | — | |
| Amortization of intangible asset | 21,546 | 79,875 | — | |
| Research and development | 2 | 4 | 5 | |
| Selling, general and administrative expenses | 29 | 8 | — | |
| Total operating expenses | 33 | 12 | — | |
| Loss from operations | −23 | −12 | −10 | |
| Interest income | 2 | 161,664 | — | |
| Grant income | 81,095 | 463,881 | 260,503 | |
| Gain (loss) on derivative liabilities and conversion of convertible debt | 88,155 | −3 | — | |
| Other expenses | −77,806 | −237,048 | — | |
| Total other income (expenses) | 2 | −3 | −4 | |
| Net loss and comprehensive loss | −21 | −15 | −14 | |
| Weighted average stock outstanding, basic (in Shares) | 18 | 7 | 4 | |
| Net loss per share, basic (in Dollars per share) | −1.17 | −2.04 | −3.84 | |
| Adjusted net loss, diluted | −21 | −15 | — | |
| Weighted average stock outstanding, diluted (in Shares) | 18 | 7 | 4 | |
| Net loss per share, diluted (in Dollars per share) | −1.18 | −2.04 | −3.84 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 66 | 49 | 1 | — | |
| Restricted cash | 58,400 | 17,872 | 90,413 | — | |
| Accounts receivable, net | 4 | — | — | — | |
| Inventory | 5 | 615,133 | — | — | |
| Prepaid expenses and other current assets | 4 | 1 | 366,316 | — | |
| Total current assets | 79 | 50 | 2 | — | |
| Other assets | — | 45,714 | — | — | |
| Equipment, net | 328,540 | 27,077 | 1,721 | — | |
| Intangible assets, net | 391,423 | 412,969 | — | — | |
| Total assets | 80 | 51 | 2 | — | |
| Accounts payable and accrued liabilities | 9 | 2 | 1 | — | |
| Current deferred income | 153,171 | — | 10,413 | — | |
| Total current liabilities | 9 | 3 | 3 | — | |
| Deferred income | 35,944 | — | — | — | |
| Option liabilities | 3 | 2 | — | — | |
| Warrant liabilities | 5 | 6 | — | — | |
| Other long-term liabilities | 47,181 | 102,783 | 84,125 | — | |
| Total liabilities | 17 | 12 | 7 | — | |
| Common stock, no par value, unlimited stock authorized, 21,742,104 and 16,019,787 shares issued and outstanding as of December 31, 2025, and December 31, 2024, respectively | 134 | 99 | 40 | — | |
| Class B preferred stock, no par value, unlimited stock authorized, 316,655 shares issued and outstanding as of December 31, 2025 and December 31, 2024 | 62 | 62 | 62 | — | |
| Additional paid-in capital | 26 | 17 | 17 | — | |
| Accumulated other comprehensive loss | −104,301 | −104,301 | −104,301 | — | |
| Accumulated deficit | −97 | −76 | −62 | — | |
| Total stockholders equity | 63 | 39 | −5 | −1 | |
| Total liabilities and stockholders equity | 80 | 51 | 2 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Depreciation and amortization | 58,572 | 81,220 | 84,479 | |
| Accrued expenditures for government grant | 53,051 | −17,515 | −80,000 | |
| Accrued interest | — | 65,996 | — | |
| Accrued interest income, related party | — | 2,550 | — | |
| Change in fair value of bonus rights liability | −55,602 | 18,658 | 75,830 | |
| Non-cash debt issuance costs | — | 459,360 | — | |
| Provision for loan losses | — | 55,000 | — | |
| Impairment of intangible assets | — | 39,166 | — | |
| Loss on disposal of equipment | 18,000 | — | — | |
| Stock-based compensation | 5 | 1 | 2 | |
| Shares issued for services | — | 2 | — | |
| Accounts receivable, net | −4 | — | — | |
| Inventories | −5 | −615,133 | — | |
| Prepaid expenses and other current assets | −2 | −671,718 | −117,271 | |
| Accounts payable and accrued liabilities | 7 | 1 | −1 | |
| Deferred income | 95,535 | — | — | |
| Net cash used in operating activities | −20 | −8 | −9 | |
| Acquisition of equipment | −293,489 | −26,701 | — | |
| Net cash used in investing activities | −293,489 | −26,701 | — | |
| Units issued for cash | — | 4 | 9 | |
| Stock issued for cash | 34 | 53 | — | |
| Stock issuance costs | −3 | −6 | −1 | |
| Warrants issued for cash | 6 | — | — | |
| Exercise of options | 364,606 | 1,800 | 27,000 | |
| Exercise of warrants | 1 | 300,000 | — | |
| Repayment of promissory notes | −911,463 | −300,000 | — | |
| Proceeds received from restricted government grant | 174,675 | 373,825 | 201,500 | |
| Amounts paid from restricted government grant funds | −134,146 | −446,366 | −111,087 | |
| Proceeds from the issuance of convertible debentures | — | 5 | — | |
| Debt issuance costs | — | −459,360 | — | |
| Net cash provided by financing activities | 38 | 55 | 8 | |
| Change in cash, cash equivalents, and restricted cash during the year | 18 | 47 | — | |
| Cash paid for interest | 4,894 | 37,754 | 59,777 | |
| Reallocation of fair value of share options upon exercise | 410,585 | 126,832 | 1 | |
| Reclassification of derivative liability of warrants exercised | 903,245 | — | — | |
| Reclassification of derivative liability for warrants re-priced from CAD to USD exercise price | — | 4 | 4 | |
| Recognition of Option liabilities | — | 2 | — | |
| Common shares issued for share issuance costs | — | 928,874 | 618,004 | |
| Warrants issued for share issuance costs | — | 3 | 402,166 | |
| Common shares issued for services | — | 2 | — |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Alpha Cognition Inc.'s CIK number?
Alpha Cognition Inc.'s SEC CIK number is 0001655923 (1655923). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Alpha Cognition Inc.'s SEC filings?
All of Alpha Cognition Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Alpha Cognition Inc. last report earnings?
Alpha Cognition Inc. (ACOG) most recently filed an earnings 8-K with the SEC on Mar 26, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001213900-26-034778). This is Alpha Cognition Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is Alpha Cognition Inc.'s most recent earnings 8-K?
Alpha Cognition Inc.'s latest earnings 8-K (Item 2.02) was filed Mar 26, 2026 under accession 0001213900-26-034778. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Alpha Cognition Inc.'s latest earnings 8-K →
Look up any company's CIK number →